USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Moderna and Merck report reduced melanoma recurrence risk with personalized cancer vaccine

The Motley Fool ·

MRNA Moderna Inc
$200.10 -1.25%
View chart & analysis →
MRK -1.34%
  1. 1Moderna and Merck reported that adding the personalized cancer vaccine Intismeran Autogen to Keytruda reduced the risk of melanoma recurrence after surgery.
  2. 2Moderna solidified its position as a platform company by succeeding in 6 out of 7 Phase 3 clinical trials.
  3. 3Moderna's stock price rose 177% in a single day, representing a year-to-date increase of nearly 580%.

So what's the key point?

Moderna and Merck announced that using a cancer vaccine together reduced skin cancer recurrence. Following this news, Moderna's stock price rose 177% in one day.

Source The Motley Fool · View original ↗

Related 3-line summaries

Moderna shares fall 17% in a single trading day The Motley Fool +1 · yesterdayModerna shares plunge nearly 20% following cancer vaccine data leak Investor's Business Daily +19 · yesterdayUS Stocks Rise; Meta Platforms Ordered to Pay $25 billion in Damages Stocktwits +2 · 2d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news